Gt biopharma abstract on novel b7-h3 immune checkpoint targeting broad spectrum solid and hematologic malignancies accepted for presentation at esmo io congress 2021

Beverly hills, calif., nov. 30, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® protein biologic technology platform, today announced that an abstract was accepted for presentation at the upcoming european society for medical oncology ("esmo") immuno-oncology ("io") congress 2021 to be held december 8-11, 2021 in geneva switzerland.
GTBP Ratings Summary
GTBP Quant Ranking